Does VEDOLIZUMAB Cause Product dose omission issue? 3,078 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 3,078 reports of Product dose omission issue have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 4.2% of all adverse event reports for VEDOLIZUMAB.
3,078
Reports of Product dose omission issue with VEDOLIZUMAB
4.2%
of all VEDOLIZUMAB reports
47
Deaths
859
Hospitalizations
How Dangerous Is Product dose omission issue From VEDOLIZUMAB?
Of the 3,078 reports, 47 (1.5%) resulted in death, 859 (27.9%) required hospitalization, and 9 (0.3%) were considered life-threatening.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 3,078 reports have been filed with the FAERS database.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which VEDOLIZUMAB Alternatives Have Lower Product dose omission issue Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB